Vanguard Global Advisers
NMRA icon

Vanguard Global Advisers’s Neumora Therapeutics NMRA Stock Holding History

Vanguard Global Advisers’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.7K Hold
31,005
– – ﹤0.01% 3042
2026
Q1 		$60.5K Buy
+31,005
New +$80.3K ﹤0.01% 2940

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Global Advisers's NMRA Position: Q2 2026 in Review

Vanguard Global Advisers held its Neumora Therapeutics (NMRA) position steady in Q2 2026 at 31,005 shares worth $52.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3042.

Vanguard Global Advisers first reported a position in NMRA in Q1 2026 and has held it in 2 quarters since. The position peaked at $60.5K in Q1 2026. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Vanguard Global Advisers held 31,005 shares of Neumora Therapeutics worth $52.7K as of Q2 2026.
  • Vanguard Global Advisers left its Neumora Therapeutics share count unchanged in Q2 2026.
  • Neumora Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3042 holding.
  • Vanguard Global Advisers first reported a position in Neumora Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Neumora Therapeutics position peaked at $60.5K in Q1 2026.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.